Us Bancorp \De\ C4 Therapeutics, Inc. Transaction History
Us Bancorp \De\
- $78.3 Billion
- Q2 2025
A detailed history of Us Bancorp \De\ transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 11,000 shares of CCCC stock, worth $24,640. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,000
Previous 11,600
5.17%
Holding current value
$24,640
Previous $18,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CCCC
# of Institutions
109Shares Held
61.6MCall Options Held
18.8KPut Options Held
0-
Lynx1 Capital Management LP San Juan, PR7.1MShares$15.9 Million4.2% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$15.6 Million0.92% of portfolio
-
Orbimed Advisors LLC San Diego, CA6.83MShares$15.3 Million0.34% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.72MShares$15.1 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$10.2 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $110M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...